People with immune-mediated thrombotic thrombocytopenic purpura (TTP) taking Cablivi (caplacizumab) plus immunosuppressants may need fewer therapeutic plasma exchange sessions than previously thought, a small study suggests. For years, standard treatment for immune TTP, a blood clotting disorder, has included immunosuppressants plus plasma exchange (PEX), a process that filters…